Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US6285301072
Ticker MYL
Company MYLAN
Currency $
Price
Aware Investor Index (AII) 0.0148
Recommendation SELL
P/E 26.91
ROE 4.46 %
Capitalization 14,596,290,000 $
Dividend Yield 0.00 %
P/S 1.28
AII Position 598
P/E Position 376
ROE Position 639
Capitalization Position 415
Dividend Yield Position 594
Sales 11,433,900,000 $
10-Year Average Earnings 542,398,700 $
Shares Outstanding 516,500,000
Equity 12,167,100,000 $
Dividend per Share 0 $
Industry Pharmaceutical
Country United States
MYLAN Investor Relations Web Site http://www.mylan.com/investors/public-filings







Sales:

YEAR MONTH AMOUNT
2018 12 11,433,900,000.00 $
2017 12 11,907,700,000.00 $
2016 12 11,076,900,000.00 $
2015 12 9,429,300,000.00 $
2014 12 7,719,600,000.00 $
2013 12 6,909,143,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 12 352,500,000.00 $
2017 12 696,000,000.00 $
2016 12 480,000,000.00 $
2015 12 847,600,000.00 $
2014 12 929,400,000.00 $
2013 12 623,711,000.00 $
2012 12 640,850,000.00 $
2011 12 536,810,000.00 $
2010 12 223,580,000.00 $
2009 12 93,536,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 12 12,167,100,000.00 $
2017 12 13,307,600,000.00 $
2016 12 11,117,600,000.00 $
2015 12 9,765,800,000.00 $
2014 12 3,276,000,000.00 $
2013 12 2,959,907,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 12 516,500,000
2017 12 536,700,000
2016 12 520,500,000
2015 12 497,400,000
2014 12 398,000,000
2013 12 394,454,000

 












Bloomberg News for MYLAN:



Google News for MYLAN:

StreetInsider.com - 14 hours ago
Theravance Biopharma (TBPH), Mylan (MYL) Present Additional ...
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the ...
PRNewswire (press release)
Assessing What Happens If Fitch Sacks Mylan
MYL's revenue and EBITDA are in decline. Generics is experiencing a diminution in pricing power. This does not bode well. I estimate MYL's ...
Seeking Alpha - 3 days ago
Mylan: The Free Fall Continues
MYL's revenue and EBITDA declined in Q1 2019. Pricing pressure within its core generics business persists. I expect more headwinds in the ...
FinBulletin
Mylan Suffers Biggest Drop in Almost Two Decades Amid Drug Pain
Mylan NV fell the most in 19 years after the drugmaker offered no updates on a strategic review that has been going on for 10 months as its ...
Rockland Register
Earnings Preview: Mylan (MYL) Q1 Earnings Expected to Decline
The market expects Mylan (MYL) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ...
US Post News
What Might Happen Next? – Mylan NV (MYL), Flex Ltd. (FLEX)
Looking at top Wall Street opinions, Mylan N.V. (NASDAQ: MYL) has recently made its way into the research list of Wells Fargo – signaling that ...
Seeking Alpha - 9 May 2019
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
Mylan N.V. (MYL - Free Report) is scheduled to report first-quarter 2019 results on May 7, before the market opens. The company's ...
Rockland Register
Abraxas Petroleum Corporation (AXAS) And Mylan NV (MYL ...
7 analysts out of 8 Wall Street brokerage firms rate Abraxas Petroleum Corporation (NASDAQ:AXAS) as a Buy, while 0 see it as a Sell. The rest ...
Mayfield Recorder
Comparing Mylan (MYL) & Merck & Co., Inc. (NYSE:MRK)
Merck & Co., Inc. (NYSE:MRK) and Mylan (NASDAQ:MYL) are both large-cap medical companies, but which is the superior business? We will ...
FinBulletin
Quant Scorecard & ROA in Focus For Mylan NV (NasdaqGS:MYL)
In reviewing some key ratios and quant data for Mylan N.V. (NasdaqGS:MYL), we note that the mother of all ratios (Return on Equity) stands at ...


Back